Nanomaterials in stroke treatment: Perspectives

Stroke

Volumn 44, Issue 8, 2013, Pages 2351-2355

  Shcharbina, Natallia ^a   Shcharbin, Dzmitry ^b   Bryszewska, Maria ^c  

^a Ministry of Health of the Republic of Belarus   (Belarus)

^b INSTITUTE OF PHOTOBIOLOGY   (Belarus)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

carbon nanotube; dendrimer; ischemia; nanoparticles; quantum dot; stroke

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARBON NANOTUBE; DENDRIMER; FERUCARBOTRAN; FIBRINOLYTIC AGENT; FULLERENE DERIVATIVE; HEPARIN; IRON OXIDE; MICROBICIDE; N ACETYL S NITROSOPENICILLAMINE; NANOMATERIAL; NANOPARTICLE; NEUROPROTECTIVE AGENT; POLYAMIDOAMINE; QUANTUM DOT; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; TISSUE PLASMINOGEN ACTIVATOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VIVAGEL;

BIOLOGY; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; HUMAN; MEDICINE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; REVIEW;

CARBON NANOTUBE; DENDRIMER; ISCHEMIA; NANOPARTICLES; QUANTUM DOT; STROKE;

HUMANS; NANOSTRUCTURES; QUANTUM DOTS; STROKE;

EID: 84880818797     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001298     Document Type: Review

References (71)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-146.
2. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic signifcance beyond thrombolysis. Pathophysiology. 2010;17:197-218.
3. Lee JM, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J Clin Invest. 2000;106:723-731.
4. Love S. Oxidative stress in brain ischemia. Brain Pathol. 1999;9:119-131. (Pubitemid 29056523)
5. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol. 1985;68:122-129. (Pubitemid 16242137)
6. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al.; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affrms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711. (Pubitemid 46691097)
7. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007;87:179-197. (Pubitemid 46860315)
8. Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30:67-99. (Pubitemid 351397456)
9. Functional Nanomaterials. Geckeler KE, Rosenberg E, eds. Valencia: American Scientifc Publishers. 2006.
10. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761-769. (Pubitemid 351556021)
11. Zhang Y, Wang TH. Quantum dot enabled molecular sensing and diagnostics. Theranostics. 2012;2:631-654.
12. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine. 2011;6:2963-2979.
13. Tomalia DA, Naylor AM, Goddard III WA. Starburst Dendrimers: Molecular-Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter. Angew. Chem. Int. Ed. 1990;29;138-175. (Pubitemid 20142204)
14. Svenson S, Tomalia DA. Dendrimers in biomedical applications-refections on the feld. Adv Drug Deliv Rev. 2005;57:2106-2129.
15. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363:2434-2443.
16. Tomalia DA, Dendritic effects: dependency of dendritic nano-periodic property patterns on critical nanoscale design parameters (CNDPs). New J. Chem. 2012;36:264-281.
17. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15:171-185.
18. Meng J, Cheng X, Liu J, Zhang W, Li X, Kong H, et al. Effects of long and short carboxylated or aminated multiwalled carbon nanotubes on blood coagulation. PLoS One. 2012;7:e38995.
19. Tasis D, Tagmatarchis N, Bianco A, Prato M. Chemistry of carbon nano-tubes. Chem Rev. 2006;106:1105-1136.
20. Erdem SS, Sazonova IY, Hara T, Jaffer FA, McCarthy JR. Detection and treatment of intravascular thrombi with magnetofuorescent nanopar-ticles. Methods Enzymol. 2012;508:191-209.
21. Chen JP, Yang PC, Ma YH, Tu SJ, Lu YJ. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Nanomedicine (Lond). 2011;6:605-615.
22. Marsh JN, Hu G, Scott MJ, Zhang H, Goette MJ, Gaffney PJ, et al. A fbrin-specifc thrombolytic nanomedicine approach to acute ischemic stroke. Int. J. Nanomedicine. 2012;7:5137-5149.
23. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci. 2007;96:2090-2106. (Pubitemid 47280103)
24. Feng X, Cheng Y, Yang K, Zhang J, Wu Q, Xu T. Host-guest chemistry of dendrimer-drug complexes. 5. Insights into the design of formulations for noninvasive delivery of heparin revealed by isothermal titration calo-rimetry and NMR studies. J Phys Chem B. 2010;114:11017-11026.
25. Bai S, Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res. 2009;26:539-548.
26. Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA. 1999;96:14529-14534. (Pubitemid 30000684)
27. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol. 2001;75:3453-3461. (Pubitemid 32225908)
28. Heegaard PM, Boas U. Dendrimer based anti-infective and anti-inflammatory drugs. Recent Pat Antiinfect Drug Discov. 2006;1: 331-351.
29. Solassol J, Crozet C, Perrier V, Leclaire J, Béranger F, Caminade AM, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol. 2004;85(Pt 6):1791-1799. (Pubitemid 38807777)
30. Supattapone S, Piro JR, Rees JR. Complex polyamines: unique prion disaggregating compounds. CNS Neurol Disord Drug Targets. 2009;8:323-328.
31. Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J. Infuence of heparin and dendrimers on the aggregation of two amyloid pep-tides related to Alzheimer's and prion diseases. Biochem Biophys Res Commun. 2006;339:577-582. (Pubitemid 41739706)
32. Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M. Infuence of dendrimer's structure on its activity against amyloid fbril formation. Biochem Biophys Res Commun. 2006;345:21-28.
33. Klajnert B, Cladera J, Bryszewska M. Molecular interactions of den-drimers with amyloid peptides: pH dependence. Biomacromolecules. 2006;7:2186-2191. (Pubitemid 44103359)
34. Heegaard PM, Pedersen HG, Flink J, Boas U. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers. FEBS Lett. 2004;577:127-133. (Pubitemid 39452372)
35. Klajnert B, Cortijo-Arellano M, Cladera J, Majoral JP, Caminade AM, Bryszewska M. Infuence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208. Biochem Biophys Res Commun. 2007;364:20-25. (Pubitemid 47599441)
36. Chafekar SM, Malda H, Merkx M, Meijer EW, Viertl D, Lashuel HA, et al. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem. 2007;8:1857-1864. (Pubitemid 47612876)
37. Rekas A, Lo V, Gadd GE, Cappai R, Yun SI. PAMAM dendrimers as potential agents against fbrillation of alpha-synuclein, a Parkinson's disease-related protein. Macromol Biosci. 2009;9:230-238.
38. Milowska K, Malachowska M, Gabryelak T. PAMAM G4 den-drimers affect the aggregation of α-synuclein. Int J Biol Macromol. 2011;48:742-746.
39. Milowska K, Gabryelak T, Bryszewska M, Caminade AM, Majoral JP. Phosphorus-containing dendrimers against α-synuclein fbril formation. Int J Biol Macromol. 2012;50:1138-1143.
40. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocom-patibility, biodistribution and biodegradation. Biochim Biophys Acta. 2011;1810:361-373.
41. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm. 2010;394:122-142.
42. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci. 2011;(120 suppl 1):S109-S129.
43. Shcharbin D, Pedziwiatr E, Blasiak J, Bryszewska M. How to study dendriplexes II: Transfection and cytotoxicity. J Control Release. 2010;141:110-127.
44. Shcharbin D, Mazur J, Szwedzka M, Wasiak M, Palecz B, Przybyszewska M, et al. Interaction between PAMAM 4.5 dendrimer, cadmium and bovine serum albumin: a study using equilibrium dialysis, isothermal titration calorimetry, zeta-potential and fuorescence. Colloids Surf B Biointerfaces. 2007;58:286-289. (Pubitemid 46921468)
45. Doerfer A, Engelhorn T, Heiland S, Knauth M, Wanke I, Forsting M. MR contrast agents in acute experimental cerebral ischemia: potential adverse impacts on neurologic outcome and infarction size. J Magn Reson Imaging. 2000;11:418-424. (Pubitemid 30185882)
46. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003;50:411-416. (Pubitemid 36950862)
47. Jander S, Schroeter M, Saleh A. Imaging infammation in acute brain ischemia. Stroke. 2007;38(suppl2):642-645. (Pubitemid 46184233)
48. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS infamma-tory lesions. AJNR Am J Neuroradiol. 2005;26:2290-2300.
49. Kim D, Chun BG, Kim YK, Lee YH, Park CS, Jeon I, et al. In vivo tracking of human mesenchymal stem cells in experimental stroke. Cell Transplant. 2008;16:1007-1012. (Pubitemid 351732842)
50. Riegler J, Liew A, Hynes SO, Ortega D, O'Brien T, Day RM, et al. Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials. 2013;34:1987-1994.
51. Sopala M, Schweizer S, Schäfer N, Nürnberg E, Kreuter J, Seiller E, et al. Neuroprotective activity of a nanoparticulate formulation of the glycineB site antagonist MRZ 2/576 in transient focal ischaemia in rats. Arzneimittelforschung. 2002;52:168-174. (Pubitemid 34252581)
52. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of super-oxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009;23:1384-1395.
53. Yun X, Maximov VD, Yu J, Zhu H, Vertegel AA, Kindy MS. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab. 2013;33:583-592.
54. Liu X, An C, Jin P, Liu X, Wang L. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials. 2013;34:817-830.
55. Ishii T, Fukuta T, Agato Y, Oyama D, Yasuda N, Shimizu K, et al. Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfu-sion is reduced. Biochem Biophys Res Commun. 2013;430:1201-1205.
56. Abdelhalim MA. The effects of size and period of administration of gold nanoparticles on rheological parameters of blood plasma of rats over a wide range of shear rates: in vivo. Lipids Health Dis. 2011;10:191.
57. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31:1-8. (Pubitemid 24016935)
58. Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol. 2008;3:83-94.
59. Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R, Kannan RM. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem. 2008;19:2446-2455.
60. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM. Poly(amidoamine) dendrimer-drug conjugates with disulfde linkages for intracellular drug delivery. Biomaterials. 2009;30:2112-2121.
61. Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R, Kannan RM. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem. 2008;19:2446-2455.
62. Johnson TA, Stasko NA, Matthews JL, Cascio WE, Holmuhamedov EL, Johnson CB, et al. Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers. Nitric Oxide. 2010;22:30-36.
63. Kim ID, Lim CM, Kim JB, Nam HY, Nam K, Kim SW, et al. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postisch-emic brain. J Control Release. 2010;142:422-430.
64. Kim ID, Shin JH, Kim SW, Choi S, Ahn J, Han PL, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther. 2012;20:829-839.
65. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modifed polyamidoamine dendrimer. Biomaterials. 2009;30:6976-6985.
66. Huang R, Ke W, Han L, Liu Y, Shao K, Ye L, et al. Brain-targeting mechanisms of lactoferrin-modifed DNA-loaded nanoparticles. J Cereb Blood Flow Metab. 2009;29:1914-1923.
67. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Effcient gene delivery targeted to the brain using a transferrin-conjugated polyethylenegly-col-modifed polyamidoamine dendrimer. FASEB J. 2007;21:1117-1125. (Pubitemid 46495701)
68. Sarantseva SV, Bolshakova OI, Timoshenko SI, Kolobov AA, Schwarzman AL. Dendrimer D5 is a vector for peptide transport to brain cells. Bull Exp Biol Med. 2011;150:429-431.
69. Patel SK, Gajbhiye V, Jain NK. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J Drug Target. 2012;20:841-849.
70. Karolczak K, Rozalska S, Wieczorek M, Labieniec-Watala M, Watala C. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats. Int J Pharm. 2012;436:508-518.
71. Nanotechnology Characterization Lab. http://ncl.cancer.gov. Accessed March 21, 2013.